Sagimet Biosciences reports Q1 net loss of $18.2M; plans Phase 1 combo trial with resmetirom in 2H 2025

Sagimet Biosciences Inc.

2025-Q1 EPS reported -$0.56

Q1 net loss $18.2M (vs $6.6M Q1 2024); R&D expense $15.3M (vs $5.3M). Cash $144.6M.
Phase 1 PK trial of denifanstat + resmetirom expected to start 2H 2025; data readout 1H 2026.
End-of-Phase 2 FDA interaction completed Oct 2024; Phase 3 deferred until sufficient funding secured.
Board changes: George Kemble to non-executive Chair; Beth Seidenberg appointed Lead Independent Director; Merdad Parsey to step off June 9, 2025.
License partner Ascletis completed enrollment of 480-patient Phase 3 acne trial in China; topline results expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.